Royce & Associates LP Boosts Stake in Axsome Therapeutics, Inc. (NASDAQ:AXSM)

Royce & Associates LP lifted its position in shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM) by 64.4% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 37,000 shares of the company’s stock after acquiring an additional 14,500 shares during the quarter. Royce & Associates LP owned 0.08% of Axsome Therapeutics worth $3,131,000 as of its most recent SEC filing.

Several other hedge funds have also modified their holdings of the company. B. Metzler seel. Sohn & Co. Holding AG purchased a new position in Axsome Therapeutics in the 3rd quarter valued at about $830,000. Moors & Cabot Inc. purchased a new position in Axsome Therapeutics in the 3rd quarter valued at about $200,000. Intech Investment Management LLC purchased a new position in Axsome Therapeutics in the 3rd quarter valued at about $983,000. Landscape Capital Management L.L.C. purchased a new position in Axsome Therapeutics in the 3rd quarter valued at about $585,000. Finally, Charles Schwab Investment Management Inc. lifted its stake in Axsome Therapeutics by 4.1% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 322,596 shares of the company’s stock valued at $28,992,000 after buying an additional 12,778 shares in the last quarter. 81.49% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Axsome Therapeutics

In other Axsome Therapeutics news, CFO Nick Pizzie sold 3,000 shares of the business’s stock in a transaction that occurred on Friday, February 14th. The stock was sold at an average price of $131.07, for a total value of $393,210.00. Following the sale, the chief financial officer now owns 42,187 shares of the company’s stock, valued at $5,529,450.09. The trade was a 6.64 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 22.40% of the stock is owned by corporate insiders.

Axsome Therapeutics Stock Up 0.9 %

AXSM stock opened at $125.90 on Thursday. The firm has a market cap of $6.14 billion, a PE ratio of -21.02 and a beta of 0.99. The company has a debt-to-equity ratio of 3.22, a quick ratio of 2.04 and a current ratio of 2.11. The firm’s 50 day moving average price is $114.75 and its 200-day moving average price is $99.65. Axsome Therapeutics, Inc. has a one year low of $64.11 and a one year high of $139.13.

Axsome Therapeutics (NASDAQ:AXSM) last announced its earnings results on Tuesday, February 18th. The company reported ($0.96) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.97) by $0.01. The company had revenue of $118.77 million for the quarter, compared to analyst estimates of $117.83 million. Axsome Therapeutics had a negative return on equity of 223.51% and a negative net margin of 74.47%. On average, equities research analysts anticipate that Axsome Therapeutics, Inc. will post -2.79 EPS for the current year.

Analyst Upgrades and Downgrades

AXSM has been the topic of a number of research reports. Truist Financial raised their price target on shares of Axsome Therapeutics from $190.00 to $200.00 and gave the company a “buy” rating in a research note on Wednesday, February 19th. William Blair reissued an “outperform” rating on shares of Axsome Therapeutics in a research note on Tuesday, February 18th. Robert W. Baird boosted their target price on Axsome Therapeutics from $132.00 to $160.00 and gave the stock an “outperform” rating in a report on Monday, March 3rd. Wells Fargo & Company boosted their target price on Axsome Therapeutics from $140.00 to $160.00 and gave the stock an “overweight” rating in a report on Wednesday, February 12th. Finally, Mizuho boosted their target price on Axsome Therapeutics from $195.00 to $212.00 and gave the stock an “outperform” rating in a report on Wednesday, February 26th. One research analyst has rated the stock with a hold rating and fifteen have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $167.36.

Axsome Therapeutics Profile

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company’s commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.